u/Dyn-O-mite_Rocketeer

Their upgrade is driven by three things: international tirzepatide growth (Mounjaro which is up 174% YoY outside the US, beating consensus by 14%), better-than-expected US GLP-1 net pricing, and the addition of non-incretin alternatives like eloralintide to their model.

They now project international sales will represent 46% of global obesity revenue by 2036. Medicare’s GLP-1 Bridge programme adds another 20 million eligible beneficiaries to the addressable base.

Plenty more upgrades to come. Whether you’re in Lilly, Novo, or Viking, just make sure you’re in.

The oral formulation looks fine. The highest oral dose (50mg) delivered up to -1.4% HbA1c reduction from baseline and 10.1% weight loss at 36 weeks. Tolerability is manageable, but nothing spectacular.

The injectable is where the problems start. The 10 to 40mg dose groups had 34 to 45% treatment discontinuation rates. The Lancet paper pins this on nausea and vomiting during dose escalation, arguing the fixed-dose protocol forced permanent withdrawal on anyone who couldn't tolerate it. Fine.

The oral paper includes a Supplementary Table 8 detailing exactly which adverse events caused patients to quit. The injectable appendix, despite a near-identical structure, has no equivalent table. Draw your own conclusions.

The HbA1c numbers are a big concern. From a baseline of 7.8%, the highest SC dose (40mg) delivered -1.71%. Tirzepatide in SURMOUNT-2 achieved roughly -2.1% from an almost identical baseline of 8.0%. Retatrutide in TRANSCEND-T2D-1 hit -2.0% from 7.9%. Zenagamtide is supposed to be a next-generation molecule. The weight loss is good (14.6% at 36 weeks, no plateau visible), but glycaemic control lags behind both current and incoming competitors at matched baselines.

As I see it, three questions need answering before Phase 3:

• Will the discontinuation table for the SC arm be published? It is becoming a bad habit the way Novo has been withholding safety data.
• Can a flexible dosing protocol bring those dropout rates to something commercially viable?
• And does the calcitonin receptor component of this DACRA molecule create an inherent ceiling on glycaemic efficacy that no dose optimisation can fix?

Disclosure first: I'm a long-time Novo holder, bought Viking shares in 2025.

Below is a condensed version of my fortress balance sheet analysis incorporating the H1 2026 interim results (reported yesterday, 4 August 2026), followed by my M&A thesis on Viking Therapeutics. Both documents run about 15 pages and 30 pages respectively, with DCF tables, probability trees and more. This is the un-TLDR TLDR version.

Novo reported Q2 adjusted operating profit up 11%, guidance raised, FCF outlook upgraded by roughly 22% at midpoint and oral Wegovy past five million prescriptions. The stock dumped more than 6% on these results and there is no rationale for that. The "new" CagriSema inferiority info on page 20 is not news either. CagriSema vs. tirzepatide as a commercial story is settled. My read is that we are shaking out the last of the dummies when it comes to negative sentiment. There is truly great stuff going on.

Doustdar announced on the morning PR call that 1.5 million people are currently on oral Wegovy globally, of which 300K are in the UK after roughly three weeks. That is frankly absurd and were it not coming from the CEO I probably wouldn't believe it. He also confirmed Novo holds more than 90% of global oral obesity sales and more than 50% market share in the UAE despite Lilly launching Foundayo about a month earlier.

On the timing, they released financials yesterday probably because EU disclosure rules require management to immediately share information if new guidance falls outside prior guidance by a certain range (I don't know the specific threshold). So not a "this management can't stop tripping over themselves" event as some have complained. No matter, I hope you find the below read worth your time. If financials bore you to death skip to Section 2, but fair warning, there is no TLDR. Sorry.

All Novo figures are converted from Danish kroner at 6.55 unless otherwise stated. The fortress analysis uses DKK throughout because that is how the financial statements are denominated.

1. The Fortress Balance Sheet Analysis

Fortress analysis answers one question: can this company survive a scenario where markets drop ~50%, interest rates spike ~8% and credit spreads blow out to crisis levels, all at the same time?

The framework came out of banking with Jamie Dimon being its most famous proponent, but it applies universally. It evaluates companies across four dimensions: leverage (how much debt relative to earnings and equity), liquidity (can you pay bills coming due), cash generation (does the business produce real cash, not just accounting profits) and profitability (does the core business model work).

Companies with fortress balance sheets don't just survive severe downturns, they can go on offence at their leisure.

This assessment uses the H1 2026 financial report and balance sheet figures are as of 30 June 2026. Flow-based metrics use trailing twelve months (July 2025 through June 2026). Two of ten metrics are left out on interim disclosure limitations, leaving eight for this exercise. I will walk through the key numbers and then show how every metric moved since the FY2025 annual assessment.

1.1 Metrics Left Out

Two metrics cannot be assessed from the interim filing.

Interest Coverage: The interim income statement reports aggregate financial income and expenses without note-level breakdown. My framework requires income statement interest expense on debts and borrowings specifically, not cash interest paid and not total financial expenses. FY2025 interest coverage was 30.3x. Total borrowings increased modestly from DKK 131 billion to DKK 140 billion. Even using total financial expenses as a worst-case denominator, TTM coverage stays well above any reasonable stress threshold. There is no plausible framing in which this metric deteriorated meaningfully.

FCF Margin, 5-year average: Novo redefined free cash flow from 2026 as operating cash flow less purchases of PP&E only, excluding intangible capex, acquisitions and lease payments. Comparatives were restated for H1 2025 but the full five-year series cannot be rebuilt from this filing. FY2025 came in at 14.7% on the old definition, which included the DKK 82.1 billion Catalent acquisition that created a negative 2024 FCF. Under the new definition that acquisition is excluded, so the directional movement is strongly upward.

1.2 One-Off Items

Two large non-cash items distort the reported numbers.

In Q1 2026, Novo reversed DKK 26.8 billion in 340B Drug Pricing Program rebate provisions as revenue recognition following favourable Administrative Dispute Resolution rulings. This inflates reported revenue, EBITDA and net profit but has zero cash impact. Unadjusted OCF/EBITDA would put a clean numerator over an inflated denominator and understate cash conversion. I use adjusted EBITDA (excluding the 340B reversal) as the denominator wherever EBITDA appears.

In Q2 2026, Novo recorded DKK 6.3 billion in non-cash impairment charges on intangible pipeline assets, of which DKK 4.0 billion relates to the termination of monlunabant. These are already added back in EBITDA (which adds back all impairments), so they only affect EBIT and net profit. For adjusted net profit I use Novo's own non-IFRS adjusted figures from the interim filing.

A second restatement issue: effective 1 January 2026, Novo moved interest received from operating activities to investing activities and interest paid from operating activities to financing activities. The interim restates H1 2025 on the new basis, but FY2025 was published on the old basis. Mixing them in a TTM formula would produce a wrong OCF number. I rebased FY2025 OCF using the annual report's own disclosed interest figures: FY2025 OCF of DKK 119,102 million, less interest received of DKK 1,398 million, plus interest paid of DKK 3,419 million, gives a rebased FY2025 OCF of DKK 121,123 million.

1.3 The Numbers

Net Debt/EBITDA: 0.61x. Net debt of DKK 86.5 billion (total borrowings of DKK 140.1 billion less lease liabilities of DKK 8.6 billion, less cash of DKK 44.5 billion and marketable securities of DKK 0.5 billion) against TTM adjusted EBITDA of DKK 142.5 billion. Novo could retire all net debt in about 7 months of operating earnings. Improved from 0.64x at year-end despite total borrowings rising DKK 9.2 billion, because cash nearly doubled to DKK 44.5 billion on strong H1 operating cash flow of DKK 79.3 billion.

Debt-to-Equity: 63.3%. Total borrowings of DKK 140.1 billion against total equity of DKK 221.3 billion. Improved from 67.5%. Equity grew DKK 27.2 billion in H1, driven by net profit of DKK 69.5 billion less dividends of DKK 35.3 billion and buybacks of DKK 5.9 billion.

Current Ratio: 0.87x raw, 2.11x adjusted. Current assets of DKK 208.7 billion against current liabilities of DKK 239.1 billion. The reported ratio looks terrible and the reason is DKK 140.2 billion in current sales deduction liabilities. These are US pharmaceutical rebate programme accruals (Managed Care, Medicare Part D, Medicaid, 340B), contra-revenue accruals settled against future wholesale billings, not operational debts requiring independent cash outflow. Strip them out and adjusted current liabilities are DKK 98.9 billion, giving 2.11x.

Quick Ratio: 0.66x raw, 1.59x adjusted. Same dynamic. Liquid current assets (excluding DKK 51.4 billion in inventories) of DKK 157.3 billion against adjusted current liabilities of DKK 98.9 billion. Improved from 1.49x adjusted at year-end, driven by DKK 18.0 billion increases in both trade receivables and cash.

Cash-to-Debt: 32.1%. Cash and securities of DKK 45.0 billion against total borrowings of DKK 140.1 billion. Up from 20.6% at year-end. Cash nearly doubled on strong H1 operating cash flow.

OCF/EBITDA: 94.0%. TTM operating cash flow of DKK 133.9 billion (rebased FY2025 of DKK 121.1 billion less restated H1 2025 of DKK 66.5 billion plus H1 2026 of DKK 79.3 billion) against TTM adjusted EBITDA of DKK 142.5 billion. For every DKK 1.00 of adjusted EBITDA, DKK 0.94 converts to actual operating cash flow. Up from 79.6% at year-end. The improvement reflects both the removal of the 340B distortion from the denominator and genuinely strong underlying cash conversion.

ROE: 52.8%. TTM adjusted net profit of DKK 102.8 billion against average equity of DKK 194.7 billion. Down from 60.7% in absolute terms but still extremely high. The decline reflects equity growing faster than the return rate can keep up, even with DKK 41.2 billion returned to shareholders in H1. A good problem to have.

Net Profit Margin: 34.0%. TTM adjusted net profit of DKK 102.8 billion on TTM adjusted revenue of DKK 302.7 billion. Stable from 33.1% at year-end. One-third of adjusted revenue converts to bottom-line profit despite competitive pricing pressure, a 6% decline in the DKK/USD rate and the ongoing restructuring.

Progression from FY2025 to H1 2026

Metric	FY2025	H1 2026	Movement
Net Debt/EBITDA	0.64x	0.61x	Improved
Debt-to-Equity	67.5%	63.3%	Improved
Adj. Current Ratio	2.09x	2.11x	Stable
Adj. Quick Ratio	1.49x	1.59x	Improved
Cash-to-Debt	20.6%	32.1%	Improved
OCF/EBITDA	79.6%	94.0%	Improved
ROE	60.7%	52.8%	Down but still high
Net Profit Margin	33.1%	34.0%	Stable

Every scoreable metric either held or improved.

1.4 Offensive Capacity

At TTM adjusted EBITDA of DKK 142.5 billion, Novo could carry roughly DKK 285 billion in net debt before reaching 2.0x leverage. That implies about DKK 199 billion (~$30 billion) in additional borrowing capacity beyond the current DKK 86.5 billion in net debt. Credit ratings remain Aa3 (Moody's) and AA (S&P). The EUR 30 billion Euro Medium Term Note Programme has capacity remaining after EUR 15.0 billion and CHF 1.09 billion in outstanding bonds.

The free cash flow outlook was upgraded from DKK 36-46 billion to DKK 45-55 billion. H1 2026 alone generated DKK 55.3 billion in free cash flow, already at the top of the new full-year range, driven by strong operating cash flow and lower capex. When a company is pulling in this kind of cash, the capacity to absorb a large transaction becomes a function of willingness, nothing more.

The forward-looking consideration is the January 2027 list price cuts (~50% for Wegovy, ~35% for Ozempic), which will reduce cash flow and mechanically increase leverage ratios on future earnings. That makes the current window the right time to act if Novo intends to act.

2. The One-Molecule Company

Three quarters of Novo's revenue comes from semaglutide. The concentration has actually increased since the FY2025 assessment: from 73.9% to 75.5% in H1 2026, driven by continued Wegovy growth. Ozempic did $9.0 billion in H1 2026 adjusted sales, Wegovy injectable $5.8 billion, oral Wegovy $0.8 billion, Ozempic pill (formerly Rybelsus) $1.5 billion. That is $17.1 billion of semaglutide revenue against $22.7 billion in total adjusted net sales for the half. 75.5% of the company riding a single molecule.

US patent expires December 2031, generics have already launched in India and been approved in Canada. When the patent falls in the US, generic entry follows in 2032.

Novo's plan is CagriSema, a combination of semaglutide with an amylin analogue called cagrilintide. In February, REDEFINE 4 reported results of an 84-week head-to-head against tirzepatide in 809 adults with obesity. CagriSema produced 23.0% weight loss. Tirzepatide produced 25.5%. The primary endpoint of non-inferiority was not met.

It gets worse when you look at the real-world number. The "treatment-regimen" figure counts every patient who actually started the drug, including those who stopped or reduced dose. Those are the patients who matter commercially, because a prescription that gets abandoned generates no revenue past month three. On that measure, CagriSema came in at 20.2% against 23.6% for tirzepatide.

CagriSema will find a market segment, since it is of course a clear improvement on Ozempic. But a failed head-to-head against the direct competition, which you yourself ran, makes it commercially dead as the next-gen platform Novo needs to move on from semaglutide.

The Q2 report adds more evidence, though none of it surprising. REIMAGINE 4, the open-label head-to-head of CagriSema 2.4/2.4mg against tirzepatide 15mg in type 2 diabetes, met non-inferiority for weight reduction (15.2% versus 15.8% at 68 weeks) but failed non-inferiority for HbA1c (1.9 percentage points versus 2.2). CagriSema keeps coming up short against the direct comparator. Novo has initiated a high-dose CagriSema phase 3 (2.4mg/7.2mg versus 2.4mg/2.4mg versus semaglutide 7.2mg), but that readout is not expected until the first half of 2028. I don't know why they even bother at this point.

2.1 Lilly Is Compounding Like It's Nobody's Business

Lilly reported Q2 2026 revenue of $23.0 billion, up 48%, driven by a 60% increase in volume partially offset by a 13% decline in realised prices. Mounjaro did $9.9 billion in a single quarter, up 91%. Zepbound did $4.9 billion, up 44%. Foundayo posted $98 million in its first partial quarter of sales, which is a decent launch but not yet material at any scale. Full-year guidance was raised to $85 to $87 billion from $82 to $85 billion, with performance margin guided up to 49.0 to 50.5%. Per IQVIA prescription data through late June 2026, Lilly holds 60.9% of the total US incretin market against Novo's 38.8%, up from roughly 53% a year ago. Internationally, the crossover has already occurred: Lilly now controls 54.9% of the ex-US market against Novo's 45.1%, on 74% market growth. Tirzepatide alone (Mounjaro + Zepbound) accounted for nearly two thirds of Lilly's total revenue this quarter.

Lilly is also using the Medicare GLP-1 Bridge programme to structurally expand the addressable market in a way Novo cannot match with injectable-only delivery. Approximately 20 million patients are now eligible at $50 per month out of pocket, with 60 to 70% being new incretin starts and a 35% increase in US covered lives for Lilly obesity medicines.

In May, TRIUMPH-1 delivered 28.3% weight loss at 80 weeks on the 12mg dose. A subset of patients who continued to 104 weeks hit 30%. Two weeks ago, TRIUMPH-2 and TRIUMPH-3 followed: 20.8% in the diabetes population and 22.6% in the cardiovascular population. Lilly has indicated a regulatory submission for retatrutide in obesity is now expected in 2027, which puts approval somewhere in late 2027 or early 2028.

Lilly already has the best-selling drug in this class, with tirzepatide on track to do $55 billion in annualised revenue. Everything Lilly does on M&A and R&D is made possible by tirzepatide. Everything. And Lilly is deploying the cash aggressively. Year to date, they've spent $15.3 billion on business development alone, including the completed acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company, plus the announced AtaiBeckley deal expected to close in Q3. On top of that: $6.0 billion in R&D and $5.2 billion in capital investments. That is $26.5 billion deployed into growth in the first half of the year, before a dollar of shareholder returns. The $2.8 billion acquired IPR&D charge booked in Q2 speaks to how much of that M&A spending is going towards early-stage science rather than near-term revenue.

The pipeline is staggering in scale. The select pipeline slide lists more than 30 Phase 2 and Phase 3 programmes across cardiometabolic, oncology, neuroscience, immunology and infectious disease verticals. Retatrutide alone is running nine Phase 3 trials simultaneously. Orforglipron has twelve. Eloralintide, which barely existed in the public consciousness a year ago, has six Phase 3 programmes initiated. Brenipatide is in Phase 3 for major depressive disorder and alcohol use disorder, with Phase 2 trials running in schizophrenia, bipolar disorder, opioid use disorder, tobacco use disorder, asthma and IBS. No other pharma company is running this many late-stage programmes off a single economic lever. All of this to say, Novo can and should be operating at this level.

Apologies for the detour, back to retatrutide which delivers even better weight loss than tirzepatide but the tolerability profile is rough. That part matters a great deal, because tolerability will drive sales going forward. TRIUMPH-1 at the 12mg dose came in at 42.4% nausea, 25.3% vomiting, 32.0% diarrhoea and 26.1% constipation, with 11.3% discontinuing due to adverse events. Compare that to tirzepatide 15mg in SURMOUNT-1: 31.0% nausea, 12.2% vomiting, ~23% diarrhoea and ~9.5% constipation, with ~6.6% discontinuing. Retatrutide buys roughly three extra percentage points of weight loss for double the vomiting and triple the constipation. The latest weight loss numbers for molecules in development like retatrutide and UBT251 are already pushing what is considered healthy weight loss, so tolerability will take centre stage going forward.

2.2 Novo's Pipeline Gap

Oral Wegovy is clearly a massive hit with more than 265,000 weekly prescriptions in the US as of mid-July, with total Q2 prescriptions reaching about 2.9 million. But the reported numbers understate true demand. Novo has guided analysts that IQVIA captures only 60 to 65% of actual prescriptions because most online and telehealth volume is still not in the IQVIA data.

And then there is what is happening outside the US. Doustdar confirmed 1.5 million people on oral Wegovy globally, with an estimated 300,000 in the UK alone after roughly three weeks. That took nearly two months in the US. In the UAE, where Lilly launched Foundayo about a month earlier, oral Wegovy has already captured more than 50% of the oral obesity market. Novo holds more than 90% of global oral obesity sales. Production is running without supply constraints, Germany is expected to launch by end of August with more EU markets to follow. All those US analysts who assumed Foundayo would dominate the oral segment and that oral Wegovy would do under $400 million in 2026 with peak sales below $2 billion are looking very dumb indeed.

To put the guidance trajectory in context: Novo's own full-year guidance started at -5% to -13% adjusted sales decline in February. After Q1 it narrowed to -4% to -12%. Today it narrowed again to 0% to -6%. The Q2 beat was a genuine surprise. Nobody (including me) had positive adjusted growth for the quarter, yet it came in at +7% CER. Ozempic landed well above estimates, partly on US rebate adjustments but also on better-than-expected international volumes. Even excluding the Ozempic US surprise, the underlying performance was better than anyone had modelled.

I think it is entirely possible oral Wegovy generates over $10 billion in annualised revenue by 2028. Incredible execution from Novo.

But..it is still semaglutide. Same molecule, same patent expiry. A higher-dose version (Wegovy HD at 7.2mg) pushes weight loss toward 21%, but the GI side-effect rate was 70.8% of patients. And each pill requires roughly ten to twenty times the active ingredient of the injection because oral bioavailability with the SNAC absorption enhancer is about 1%.

On margins, the market may be misreading the Q2 numbers. Reported gross margin came in at 78.2% versus 82.7% last year, and some will jump to the conclusion that this proves the pill is margin-dilutive. Novo took roughly DKK 3 billion in one-time costs related to right-sizing manufacturing capacity agreements, including a fill-finish expansion here in DK. Strip that out and underlying gross margin was about 82%, roughly flat year-on-year. I missed this yesterday when commenting on the early release. Management has also told analysts that the pill's gross margin is comparable to the overall reported gross margin, so the pill is not the profitability drag some have feared. Revenue is growing and the margin on the growth product is holding.

There is a potential 2027 catalyst not getting enough attention as well. The FDA has accepted a filing to add the MASH indication to the oral Wegovy label, with a decision expected in Q1 2027. If approved, MASH labelling opens an insurance coverage pathway for patients who currently cannot get prescriptions covered for obesity alone. That could meaningfully boost insured-channel uptake.

On top of all this, the Medicare Bridge programme went live on 1 July with encouraging early uptake. Novo receives a flat $245 per dose on Bridge prescriptions regardless of strength, above the current blended average selling price of roughly $169 in the self-pay channel. Symphony data pointed to more than 7,000 Bridge prescriptions in the week ending 24 July and the trend is increasing week by week. Very little Bridge revenue is included in the new guidance range, and neither is the EU launch of oral Wegovy. Genuine upside catalysts for the second half.

We've talked about CagriSema, but what about Novo's other internal candidates? They are years away. Zenagamtide (formerly amycretin) reported 14.6% weight loss at 36 weeks at ADA in June. It is a GLP-1/amylin agonist, the same receptor combination that lost to tirzepatide in REDEFINE 4. It will not reach registrational results before 2029 at the earliest. Today's report confirmed two new zenagamtide phase 3 initiations (AMAZE 8 for obesity, readout first half 2029; HF-POLARIS for heart failure outcomes, readout second half 2029), but those are years from commercial relevance. NN419, a GLP-1/GIP/amylin triple agonist, does not read out from Phase 1b/2 until H1 2027, which means it cannot complete registration before roughly 2030. Today's Q2 report also included a roughly $1 billion write-down on pipeline assets including monlunabant, a programme that has been dead for over a year. They are just now taking the non-cash impairment. Separately, the ZEUS cardiovascular trial with ziltivekimab failed its primary endpoint last week.

So Novo keeps writing cheques on internal programmes, the amylin bets in particular, and the returns keep disappointing. What I'm sure was already ongoing internal debate is now a public call for M&A from analysts and major investors alike.

2.3 What Novo Needs

The gap to tirzepatide is mechanistic and no matter what Doustdar says, you cannot simply jack up the semaglutide dose and hope to keep up. Novo has no dual GLP-1/GIP offering, the receptor combination that makes tirzepatide work.

There is however one late-stage dual GLP-1/GIP agonist not owned by Lilly. VK2735, made by Viking Therapeutics. Viking is a clinical-stage company in San Diego with about $502 million in cash at the end of Q2 and no revenue. Its Phase 3 programme, VANQUISH, has over 4,500 patients enrolled in the obesity trial and about 1,000 in diabetes. Both fully enrolled, on track for 78-week readouts.

In Phase 2, the injectable version produced 14.7% weight loss in just 13 weeks on the highest dose. For context, tirzepatide produced roughly 15% at 20 weeks in SURMOUNT-1. VK2735 got there seven weeks faster, which suggests the weight-loss curve had not yet plateaued. The oral version hit 12.2% over the same 13-week period. The injectable discontinuation rate was 13% on drug versus 14% on placebo, meaning zero excess dropout from the drug itself. For comparison, GLP-1 trials typically see discontinuation rates of 6 to 15 points above placebo.

On gastrointestinal tolerability, the Phase 2 VENTURE trial (176 patients, published in the journal Obesity, January 2026) reported nausea at 43% versus 20% on placebo and vomiting at 18% versus 0% on placebo. Those raw rates are higher than tirzepatide 15mg in SURMOUNT-1 (31.0% nausea, 12.2% vomiting per the NEJM publication), but the comparison is not apples to apples. VK2735's data comes from a 13-week Phase 2 where the early titration period dominates the adverse-event window. Tirzepatide's comes from a 72-week Phase 3 where those same early events get diluted over a much longer observation period. What matters more than the headline rates is what patients actually do. VK2735 discontinuation ran at 13% versus 14% for placebo (zero excess dropout) while tirzepatide 15mg saw ~6.6% discontinue due to adverse events against a lower placebo baseline. 68% of VK2735 nausea was mild, none was severe, 95% of all GI treatment-emergent adverse events were mild or moderate, and the weekly nausea rate dropped below 5% after week one. If that tolerability profile holds at Phase 3 duration, it would be a meaningfully differentiated profile. That is a big "if" and I won't pretend otherwise. Thirteen weeks is a short window and the period from month three to month twelve is where GLP-1 dropout accelerates.

2.4 Viking's Funding

Viking ended Q2 with $502 million in cash, down from $706 million at year-end 2025. The six-month cash draw was $204 million and accelerating as the Phase 3 programme scales. Viking has already filed a $500 million shelf registration.

Viking's cash covers the VANQUISH readouts but not the full oral Phase 3 programme that follows. A company that has to raise capital before its biggest catalyst has a reason to prefer a partnership or acquisition over a dilutive equity raise.

2.5 The Cost of Doing Nothing

Most people fixate on what VK2735 is worth as a standalone. The better question is what does Novo lose without a competitive dual incretin?

Start with 2025 semaglutide profit. $34.8 billion of semaglutide revenue at roughly 33% operating margin gives about $11.5 billion of annual operating profit from one molecule. Apply the guided annual decline, model generic entry in 2032 at 20% annual erosion, and ask what fraction of the declining semaglutide patient base could be retained by converting them to a branded dual incretin before the cliff. At a 40% preventable fraction (the patients who switch on clinical preference rather than price), the present value of what Novo loses by not having a competitive next-gen asset runs between $3.5 and $6.0 billion depending on the decline rate.

That is the benchmark every deal option has to be measured against. Buying VK2735 might be very expensive on a standalone basis. Not buying anything looks more expensive when measured against what Novo loses.

The fortress analysis reinforces this. Net Debt/EBITDA at 0.61x leaves roughly $30 billion in additional borrowing headroom before reaching 2.0x. The free cash flow outlook just got upgraded to DKK 45-55 billion on the back of stronger-than-expected commercial execution. The balance sheet is just sitting there waiting for Novo to do something with it.

2.6 What I Think It's Worth

My model values VK2735 to Novo by building revenue from the bottom up: peak branded market share of 6.5% for obesity (within Viking's own guided 5 to 10% range, before Novo's commercial infrastructure), smaller shares for diabetes and a potential cagrilintide combination product, applied across two scenarios for the total branded market in the 2030s ($136 to $152 billion depending on whether the category follows the immunology or statin precedent), then discounted at 9.5% after probability-weighting for clinical, regulatory and commercial risk. The model carries 45% incremental margin rather than Novo's own 55 to 60%, because VK2735 requires solid-phase peptide synthesis under CDMO contract rather than Novo's owned yeast fermentation bioreactors. That is a genuine manufacturing disynergy and it is priced in.

My central range lands between $56 and $70 per share to Novo. $56 if the branded market erodes after tirzepatide goes generic in 2036, $70 if the branded category persists the way Skyrizi and Rinvoq persisted through Humira biosimilar entry. Across the two weakest inputs (oral margin gap and pricing inheritance) and a range of discount rates, the full sensitivity analysis runs from $44 to $79. Viking's stock sits at $32, well below the entire range. On roughly 116 million diluted shares, the central range translates to $6.5 to $8.1 billion in total consideration, or $5.9 to $7.5 billion net of Viking's cash. For scale, Novo paid $11.2 billion for Catalent, a contract manufacturer with no novel molecules.

A deal is value-positive to Novo at $60 per share, roughly $7.0 billion gross. Even at double the current share price, the probability that a Viking board accepts at $60 is low given the 52-week high of $43 and the likely VANQUISH catalyst ahead. But against the franchise-erosion benchmark, the improvement over doing nothing is $4.7 billion. At $73 (~$8.5 billion gross), the standalone DCF turns slightly negative, but the franchise-preservation case still supports it. That is exactly how AstraZeneca justified $39 billion for Alexion and BMS justified $74 billion for Celgene. Novo's own buyback programme currently offers a forward earnings yield near 6.8% with no clinical, regulatory or manufacturing risk. A Viking acquisition beats that return below roughly $8.5 billion and loses to it above.

2.7 What Could Go Wrong

VANQUISH-1 could miss. I put that at 5% because every placebo-controlled Phase 3 of an incretin agent on a weight endpoint (STEP, SURMOUNT, SURPASS, SCALE, REDEFINE 1 and 2) has hit. The mechanism is validated, the comparator is placebo, the Phase 2 curve was steep and still descending at week 13. The real risk is sub-scale: the drug works but delivers under 20% on the treatment-regimen measure, which makes it commercially competitive with generic tirzepatide rather than differentiated from it. I weight that branch at 30%. If it lands there, VK2735 is worth roughly $27 to $34 per share to Novo, not $56 to $70.

The tolerability data is from 13 weeks. The best available cross-trial comparison uses VENTURE Phase 2 (VK2735 SC, 176 patients, 13 weeks) against SURMOUNT-1 (tirzepatide 15mg, 72 weeks). On raw rates, VK2735 showed higher nausea (43% versus 31.0%) and higher vomiting (18% versus 12.2%). But the duration mismatch matters: a 13-week trial concentrates adverse events in the titration window while a 72-week trial dilutes them over a longer observation period. The more telling metric is discontinuation: VK2735 saw zero excess dropout above placebo (13% drug versus 14% placebo) while tirzepatide 15mg saw ~6.6% discontinue due to adverse events against a lower placebo baseline. Whether that pattern holds at Phase 3 scale is the open question. If VK2735 tolerability degrades materially between month three and month twelve, the persistence argument weakens and the commercial differentiation narrows. That is where the data stops until VANQUISH-1 reads out.

There is also a manufacturing integration cost. VK2735 contains non-natural amino acids that Novo's yeast fermentation infrastructure cannot produce. The API must be made by solid-phase peptide synthesis, currently contracted to CordenPharma. Novo's Catalent sites handle fill-finish, but the API production synergy is zero. Building proprietary SPPS capacity could easily run $500 million to $1 billion in capex over several years, and until then Novo carries CDMO supply chain risk on a potential blockbuster. I have already accounted for this through a lower margin assumption in the model, but it is a real cost and a real integration risk that compounds over the first few years of ownership.

As an aside, Pfizer is busy dumping Metsera assets and what data they've presented in trials looks like Novo dodged a bullet. Whether Doustdar deliberately bled Pfizer over Metsera or just got lucky remains to be seen, but Pfizer will basically be releasing its GLP-1 offering equivalent to semaglutide just as semaglutide goes generic. Good luck with that.

2.8 My Verdict

Novo beat on Q2. Adjusted sales grew 7% CER in a quarter where the street modelled a decline. Guidance raised for the third time this year. FCF outlook jumped from DKK 36-46 billion to DKK 45-55 billion. Every fortress metric held its band or upgraded, zero downgrades, 94% of EBITDA converting to operating cash flow. Novo remains a certified cash machine for now.

Oral Wegovy is already an extraordinary story. Five million prescriptions since January, 1.5 million active users globally, 300K in the UK after three weeks, 90%+ of global oral obesity sales, Germany and EU launching in weeks, Bridge just starting, MASH filing accepted by FDA. And almost none of the international launch or Bridge revenue is in the new guidance. A lot of sell-side analysts are still totally asleep on this.

Fortress-grade financials and a blockbuster oral launch buys time, they do not close the clinical gap to Lilly and the amylin bets keep coming up short.

The only available late-stage dual incretin Novo can buy is VK2735, the market prices Viking at $32, my model says Novo should pay $55 to $65 (I don't consider Pfizer's Metsera debacle instructive for M&A in any way). If the Phase 3 readout is competitive with tirzepatide, expect a bidding war and for that price to at least double my low-end estimate. The longer you wait, the more you will likely pay. Or worse, someone else pays it.

I want free movement, open trade and a continent that can defend itself, and I'll argue for all three in any room you put me in.

What I'm against is bloat. Technocracy. A permanent administrative class that answers to nobody, grows regardless of results and has never once concluded that the answer might be less of itself. That is what Brussels has become.

Maastricht was meant to be a beginning. A first attempt at a shape, drawn up on the explicit understanding that the shape would keep changing as Europe worked out what actually functioned. The form froze. The powers kept expanding. The machinery got heavier, accountability got thinner, and the people operating it started treating their own first drafts as gospel.

So what follows is my European argument. It just doesn't run through Brussels. It runs through Copenhagen, Helsinki, Oslo, Stockholm and Reykjavik, and it comes in three stages: build the union, vote as one bloc inside the system, then leave together on our own terms if the arithmetic below still holds.

The arithmetic

Start with how EU laws actually pass. To stop something you don't want, you need a blocking minority: four member states holding over 35% of the EU population. Sweden, Denmark and Finland together hold roughly 22 million people. Under 5% of the Union, and three countries out of the four required.

So we can't block anything. We can't even reach the threshold that forces the Council to sit down and compromise with us. And we pay for the seats at this table. In 2024 Sweden was a net contributor of €2.3 billion, Denmark €1.0 billion, Finland €385 million, on the Commission's own numbers. Call it €3.7 billion a year for a vote that cannot, under any coalition available to us, change a single outcome.

"But the vote doesn't matter, membership buys you the single market!"

Okay. Let's look at what it buys.

What membership actually buys

The single market you are being asked to stay for is unfinished, ignored by its largest beneficiaries and going backwards.

The European Central Bank puts the hidden barriers inside it at the equivalent of a 65% tariff on goods and up to 100% on services. Roughly 60% of those services barriers haven't moved in twenty years, and intra-EU trade in services sits at 7.9% of GDP. Our economies are services economies. That number alone should decide the whole argument.

The Commission's own 2026 Annual Single Market and Competitiveness Report admits integration has plateaued, with six of its 29 indicators moving the wrong way, and gives the worst offenders a name: the Terrible Ten. The European Court of Auditors found in 2026 that Commission action on cross-border services was still insufficient, and that its recommendations to Germany, France, Italy and Hungary produced exactly nothing.

Then there's who actually obeys the rules. Germany and France took 77% of the €672 billion approved under the emergency state aid schemes, meaning government subsidies to their own companies, while accounting for roughly 42% of EU GDP. That figure is straight from Margrethe Vestager's own letter to member states as competition commissioner. Under the COVID scheme, more than half of all the aid the 27 put up for approval was German. Berlin spent only a fraction of it in the end, which is the point: it had the fiscal room to reserve half of Europe's crisis firepower for its own industry, and nobody else did. In 2022 Berlin unveiled a €200 billion energy package without so much as a heads-up to Paris. Macron called it a risk of isolation, Draghi called it divisive and Orbán called it cannibalism (he'd know).

Then the rules themselves. Germany slapped a "neutrality charge" on cross-border gas trades, a tariff on other Europeans in all but name, which the EU's own energy commissioner said put energy solidarity at risk. It took two years of condemnation and a legal threat from Austria before Berlin dropped it at the start of 2025. In March 2023, days before the final vote on a law the Parliament and Council had already agreed, Germany pulled its support for the 2035 combustion engine ban and walked away with an exemption for e-fuels, which happens to suit its car industry. Italy, Poland and the Czech Republic piled in behind Germany to force the exception through.

The Mobility Package required trucks doing international haulage to physically return to base every eight weeks, which of course hits eastern European hauliers and nobody else. Seven member states took it to court, and in October 2024 the European Court of Justice annulled the return obligation, because it had never appeared in the Commission's original proposal and so was never impact-assessed. Eastern hauliers had been legally on the hook since February 2022 anyway.

Sweden threatened to restrict electricity exports outright when Brussels proposed skimming 25% of congestion revenues for EU infrastructure, given that roughly three quarters of Sweden's roughly €3 billion in congestion revenue comes from internal bottlenecks rather than cross-border electricity flows. Sweden built a clean system and split itself into four bidding zones just as Brussels asked. Germany refuses to do either. Sweden was to get the bill but last month the Council backed down: domestic congestion income stays home, and only cross-border income is touched, at 10% from 2028.

Finland tried the polite version of the same fight. Its 2023 government took office with a coalition agreement explicitly rejecting any permanent EU transfer instrument, anything that would turn the Union into a standing income transfer machine. Written into the coalition programme, argued through every proper channel. It made absolutely no difference. The state aid rules were loosened anyway in March 2023, handing the advantage straight to whoever had the deepest pockets. The European Parliament's own research frames the whole fight as German and French appetite for state intervention against smaller states' appetite for competition and free trade.

Now put those two Nordic stories side by side, because together they are the entire case for what I'm proposing. Finland objected on paper and got nothing. Sweden put its hand on the cables and got total retreat.

By this point the pattern is not subtle. Everyone does whatever they want, and the rules only bind those who can't afford to ignore them. When the rules bind the big states, the rules magically bend. The states that eat the cost are smaller, open and compliant. That would be us.

And nobody is coming to fix it

Every crisis since Maastricht arrived with a list of things Europe finally had to do.

Free movement of capital was one of Maastricht's four freedoms. More than twenty-five years after the last controls on capital moving between member states came down, European finance is still a set of national marketplaces only partly joined together. A banking union was supposed to answer the euro crisis. The Commission proposed its third pillar, a common scheme to guarantee bank deposits, in November 2015, to be built out over eight years to 2024. It's 2026 and it still doesn't exist, because Germany won't have it. Capital Markets Union launched the same year and has languished for over a decade.

Then Draghi. In September 2024 the former ECB president wrote the definitive audit of all this and warned Europe faced slow agony without radical change. His fix needs an extra €800 billion a year, close to 5% of EU GDP, against an EU budget of roughly 1%. As of July 2026, 60 of his 383 measures are fully implemented. That's 15.7%, up six-tenths of a point in six months. A separate tracker run by a different outfit puts it lower still at 11.2%, with energy reforms sitting on zero. Of the reforms that need both the Parliament and the member states to actually move, 3% are done.

This is the institution asking us to keep paying €3.7 billion a year and take whatever it decides. It has known precisely what's wrong with it for years, commissioned the diagnosis itself, formally signed up to the cure, and manages minimal implementation. Nobody is coming to reform this.

Outside is not the wilderness

Norway sits 60% above the EU average on GDP per head. Switzerland 51%, Iceland 31%. None of them are members. And yes, I can hear the objection: Norway is oil, Switzerland is banks and pharma. Fine. Iceland is fish and tourism and still clears the EU average by nearly a third. I'm not claiming that leaving makes a country rich. What collapses here is the reverse claim, repeated as though it were self-evident: that membership is what makes European countries rich. The three richest countries in Europe never joined. Switzerland also topped Europe on innovation performance in 2025, scoring 0.749 against Sweden's 0.740, the best the EU itself has to offer.

The British case gets waved around as the cautionary tale, so let's be honest about what it actually shows. Since the end of 2019 the UK, with a botched exit, no plan and four prime ministers, has grown 6.0%. Per head the picture is mediocre and I'm not holding Britain up as a model of anything. That is precisely the point. The floor for leaving, executed as incompetently as an exit can be executed, alone, is mediocrity. Meanwhile Germany, the country at the EU's heart, the one that writes the rules, has managed 0.8% over the same period, the worst in the G7. The benchmark for staying at the very core of the project is worse than the benchmark for leaving it badly.

So what does being outside actually cost? Norway has adopted roughly three quarters of EU rules with little say in writing any of them, and has used its right to refuse a new rule exactly once, over postal liberalisation. That is the standard objection to the EEA and I'm not going to pretend it away. Here is what it misses. Sweden, Denmark and Finland also adopt rules they had no meaningful say in writing. That is what sitting below the blocking threshold means in practice. The difference between our position and Norway's is a formal vote that cannot change outcomes, purchased for €3.7 billion a year. Call that what it is, a receipt.

And there's a second thing the objection misses. Norway's deal was negotiated alone, in 1994, months after losing a referendum, from the weakest position imaginable, and the 2024 Norwegian review of that arrangement still flags a real deficit in co-determination while concluding the deal has served Norway well and held up better than expected. The next version of that deal would not be negotiated by one country of five and a half million licking its wounds. It would be negotiated by a bloc holding over half the EU's imported pipeline gas and nine tenths of its iron ore.

What we actually weigh

The usual objection is that five small economies don't add up to one big one. True of countries which do the same things. Not true here. The Nordic economies barely overlap, and where they touch they're already merged.

Norway sells energy. It supplies 54% of the EU's imported pipeline gas to a bloc it has never joined, exports a volume equal to more than 30% of all the gas the EU and UK burn, and sits on the world's largest sovereign wealth fund at over $2 trillion. Sweden runs the industrial base and the mines: Volvo, Scania, Sandvik, Atlas Copco, SKF and Ericsson, plus 89% of the EU's iron ore, 46% of its lead and 45% of its zinc. The Per Geijer deposit near Kiruna holds an estimated 2.2 million tonnes of rare earth oxides, among the largest in Europe, and Greenland ranks eighth globally on rare earth reserves. Finland exports the machinery underneath much of European industry through Wärtsilä, Kone and Valmet, designs 80% of the world's icebreakers and builds 60% of them. Denmark ships pharmaceuticals and biotech worth more than a quarter of its goods exports, runs one of the world's largest merchant fleets through Maersk, Torm and Norden, and grows enough food for fifteen million, much more if we decide to reduce our pork exports. Iceland runs almost entirely on geothermal and hydro, and lands fish exports.

Nearly 28 million people, a combined GDP of roughly $1.9 trillion, and very little economic redundancy anywhere. Now let's put the pieces next to each other rather than in competition.

Ericsson and Nokia are the only two full-scale mobile network suppliers left in the Western world. They are Swedish and Finnish. Every other option is Chinese or Korean. Between them they hold the entire Western capability, split across a border neither company particularly notices.

Danish wind turbines, Norwegian hydro, Swedish and Finnish nuclear. Over 90% of Nordic electricity comes from low-carbon sources, and the whole thing runs a surplus: we exported a record net 41 TWh in 2024, mostly to Germany and Britain, and in 2025 beat it again.

Then defence, where we've gone further than most people even realise. Nammo, the Nordic Ammunition Company, was formed in 1998 by merging the ammunition arms of Norway's Raufoss, Finland's Patria and Sweden's Celsius. Today it's owned 50% by the Norwegian state and 50% by Patria, which is itself 50.1% Finnish state and 49.9% Norway's Kongsberg. Two Nordic governments jointly own a defence manufacturer through a cross-holding structure, and have done for twenty years. Patria's own executives describe it plainly: few overlaps in what the three companies make, so they cooperate instead of competing.

Nordea is a Nordic bank, not a Swedish or Finnish one. Stora Enso is Finnish-Swedish. Telia is Swedish-Finnish. TietoEVRY is Finnish-Norwegian. When Nordic firms need scale they merge across borders and nobody calls it a foreign takeover, because the legal systems, corporate governance norms and labour laws are near-identical. Try that between Paris and Berlin and you get a decade of ministerial argument, as Siemens and Alstom discovered.

And our output is absurd for a region of 28 million people. Three of the four countries in the Commission's top tier of innovators are Nordic. Europe's leading innovation region is Stockholm, with Copenhagen/Øresund right behind it. A combined population smaller than Poland's has produced Spotify, Klarna, Supercell and more, and note that none of them scaled on a home market. Nordic firms are born exporters. A single market for services that runs at 7.9% of GDP was never what carried them.

Add it up and you get an energy exporter with a $2 trillion balance sheet, the West's entire independent telecoms equipment capability, a pharmaceutical and biotech champion, Europe's iron ore and the machinery that runs much of European industry, one of the world's great merchant fleets and a world-class defence industry that is already jointly owned and highly integrated. And a power system that relies only on itself.

One diversified economy which happens to fly five flags.

Now let me be precise about the leverage, because the lazy version of this argument deserves to lose. Nobody is threatening to turn off gas to Rotterdam. Interdependence runs both ways: Novo Nordisk needs European patients, Volvo needs European roads, and Norway's fund got to $2 trillion by selling energy to this continent. But renegotiations don't ask who trades with whom. They ask who can replace whom, and how fast. The EU cannot replace Norwegian pipeline gas, Swedish iron ore or the only two Western telecoms suppliers on any timescale that matters. The Nordics, selling essentials, would find buyers, because essentials always find buyers. A new customer for insulin and container freight is easier to source than a second Ericsson. That asymmetry never needs to be exercised to be real.

Hard power

Every Nordic state with an army spends above NATO's 2% benchmark: Denmark 3.34%, Norway 3.2%, Finland 2.87%, Sweden 2.5%. Norway is the first European ally in the Alliance's history to outspend the United States per capita on defence.

Norway has completed its full 52-aircraft F-35 programme and retired its F-16s, the first nation anywhere to finish its order. Denmark has 27 and is close behind. Finland has 64 on order, with deliveries beginning. Sweden operates over 90 Gripens and is already running joint exercises with Danish F-35 pilots over the Baltic. When Finland's fleet lands, Norway, Denmark and Finland will field 143 F-35s between them, with Sweden's Gripens on top. Germany has ordered 35 and France has none. And a dedicated air operations centre in Bodø, opened in October 2025, is now NATO's third combined air command alongside Uedem and Torrejón, with responsibility for the Nordic region, the Baltic, the North Atlantic and the High North.

On the ground, Finland is in a league of its own. Its wartime strength of 280,000 trained personnel is drawn from a reserve pool that now extends to age 65, nearly one million citizens. Its artillery park, roughly 1,500 pieces, is among the largest in Europe, exceeding Germany, Norway and Sweden combined.

At sea, Nordic navies control the geography that matters most to NATO's northern flank. The Danish Straits are the only sea exit from the Baltic, and Norway covers the Norwegian Sea behind them. Sweden's Gotland-class submarines are diesel-electric and near-silent. In exercises they have evaded a US carrier strike group for days. Eleven undersea cables have been cut or damaged in the Baltic since October 2023. The joint forces being built through the Joint Expeditionary Force are a direct response to that threat.

All the Nordic states belong to the JEF, a ten-nation coalition where activity goes ahead whenever two members agree. No Brussels consensus and no unanimity requirement. Try getting that out of a room with 27 competing interests.

And now the honest paragraph, because this argument only stays credible if I write it myself before someone else does.

None of the above is autarky. The F-35s run on American sustainment chains and American software. Bodø is a NATO command. The JEF is British-led. Strip the Alliance out of the picture and it gets uglier and fast. But that cuts exactly the way we should want it to. The realistic danger of this decade is Washington's attention flickering, not NATO dissolving overnight, and the rational answer to a flickering ally is to be the part of the Alliance that still functions on a bad day in the White House. Own ammunition production through Nammo. A sovereign fighter line through Saab. A million-strong reserve that asks nobody's permission to exist. Command arrangements that activate when two members agree rather than when thirty-two do. Self-sufficiency is a direction of travel, and the Nordics are the only corner of Europe actually embarking on this journey.

Governance and soft power

Denmark topped the 2025 Corruption Perceptions Index for the eighth year running on 89. Finland second on 88. Only five countries worldwide clear 80 and three of them are Nordic. Norway is the third, on 81. Sweden sits just under on 80, Iceland on 77.

All five Nordic states sit inside the top 35 of 193 on the 2026 Global Soft Power Index, with Sweden fourth globally for governance.

How a union happens, in order

Our vehicle already exists. On 16 March 2026 Nordic governments set up a commission to redraft the Helsinki Treaty, the document Nordic cooperation actually runs on. Signed in 1962, amended seven times, last touched in 1996. The Nordic Council had already voted in 2024 to write defence and security policy into it.

And we should be clear-eyed about the pedigree, because we finished the hard parts before Brussels even started. Passport-free travel between the Nordic countries came in 1952. The common labour market followed on 2 July 1954, three years before the Treaty of Rome was even signed. The Nordic Convention on Social Security landed in 1955. A separate convention gives every Nordic citizen the right to use their own language when dealing with another Nordic country's authorities. A Dane has been able to move to Helsinki, take a job without a permit and carry their social security entitlements with them since before the European Economic Community existed. Take a bow.

Compare that with the list Brussels published in March 2026 as its priorities for the next two years: mutual recognition of professional qualifications, portability of skills, a "once-only" principle for business data, harmonised product labelling. Seventy-two years after we did the hard version, the EU is scheduling the easy version, with a deadline of end-2027 and no guarantee of getting it over the line.

What's left to fix at home is well mapped. The Nordic Freedom of Movement Council has cleared nearly 90 cross-border barriers since 2014. It took on 35 in 2024 and resolved 11. That is a body with no power beyond persuasion, clearing roughly one obstacle a month, because five sovereign tax authorities and five pension systems each have to agree separately. The council's own staff say almost every remaining obstacle traces back to the common labour market: tax, pensions, social security payments. Those are exactly the problems a union solves at a stroke and a cooperation forum cannot solve at all. One unemployment insurance entitlement that follows you from Aalborg to Tampere without a form. One pension record. One tax residency rule for anyone commuting across a Nordic border. One recognition of your nursing or engineering or teaching qualification, valid the day you qualify. One digital identity that opens a bank account in any Nordic jurisdiction. The Nordic Council adopted a strategy in October 2025 with a target of Karlstad to Kongsvinger being as easy as Uppsala to Stockholm. Good target. It will not be reached by five governments negotiating politely, and everyone involved knows this.

So, the sequence..

Stage one: build our union. Widen the treaty commission's mandate and redraft Helsinki into a federal compact. Turn NORDEFCO's Vision 2030, the joint defence plan signed in Tórshavn in April 2024, into a standing joint command under the Bodø architecture that already exists. Finance the build-out through the Nordic Investment Bank, which is AAA-rated, owned by the five Nordic states plus the three Baltics, and signed its first defence loans in 2025. Merge the labour market plumbing: the pension record, the tax rule, the digital identity. None of this requires anyone's permission but our own, and none of it requires leaving anything.

Stage two: vote as one, inside the system. Denmark, Sweden and Finland arrive at every Council meeting pre-bound to a single position. Norway and Iceland do the same on the EEA side, and all five at NATO. This is not a retreat from the argument above. It is our control experiment. We already know what three separate small voices achieve. Twenty-two million people voting as one still cannot block, but a bloc that controls the gas, the ore and much more while voting as one is a different negotiating animal entirely, and the Sweden electricity case shows Brussels retreats when leverage is stated rather than implied. Give this stage a fixed horizon, one treaty cycle, and measure it honestly.

Stage three: if the arithmetic still wins, leave together. If a unified bloc with these cards still cannot move outcomes, the case for paying €3.7 billion a year for nothing more than receipts collapses on its own evidence, and the EEA offer goes on the table. Keep the single market, drop the fee and the fiction of influence. In 1994, negotiated alone after a lost referendum, the EEA read as surrender. Tabled by a unified Nordic bloc, Brussels can then decide how much a formal vote was really worth to us, because it will finally have to price it in.

Two hard problems and let's name them now. The first is money. Finland is in the euro, Denmark is pegged through ERM II, Sweden and Norway float. A Nordic union does not need a common currency on day one, and pretending it needs one would kill the project in the crib; the EEC ran for decades without one. But the end state has to be answered eventually, and Finland's position is the single most delicate item in the entire sequence.

The second is the mandate. Between 79% and 85% of Danes, Finns, Norwegians and Swedes told a Nordic Council of Ministers survey in spring 2026 that Nordic cooperation makes them more confident about the future. That is not a mandate for union and I won't inflate it into one. It is the raw material a mandate gets built from, which is more than most European projects ever start with. Mandates are won in referendums, and referendums are won by making exactly the argument my essay makes, in public, for years. Stage one requires no referendum at all. By the time stage three does, our union will already have a record to run on.

The choice underneath it

Between the war in Ukraine, Putin and Trump, a lot of EU dysfunction is being glossed over in favour of proclaiming European unity. Nothing comes easier to a politician than a common enemy. But centrist parties across Europe keep shedding vote share. Rising support for the extreme left and the extreme right delivers violent pendulum swings, political gridlock and nothing constructive. Italy is governed from the hard right, Spain from a left-wing coalition dependent on parties well to its own left, and Germany and France both look likely to be held hostage by their extremes for years to come.

In that world, bind yourself to the people you actually trust and whose institutions actually work. Size without alignment is what the EU already has: 450 million people who agree on very little, wielded by nobody. Alignment is what converts weight into force. We have alignment. It is centuries old, it has survived everything the twentieth century threw at it, and it is sitting there waiting to be given its day.

Thank you for taking the time to read my hopes for our Nordic future.

Note: more than 60 sources were used to substantiate the arguments made above. Rather than embed them all in a hyperlink orgy, I'm listing them in a comment below for anyone who may be interested in further reading.

In January, Merz called the nuclear phaseout "a serious strategic mistake" and said Germany simply doesn't have enough generation capacity. Two months later, in March, he called the same phaseout "irreversible." His reasoning: SPD wouldn't agree to nuclear in the coalition deal. Not physics. Not economics. Political theatre.

That's essentially where the German nuclear debate has been stuck for years. Acknowledge the problem, then declare it unsolvable because of politics.

Last week, former nuclear plant managers published a letter in Bild addressed directly to Merz and his coalition, urging them to seriously examine restarting reactors. Their message boils down to: the technical knowledge, the sites, the infrastructure, parts of the plants and portions of the workforce are still there. But you don't have much time. Every month of continued decommissioning makes restarts harder and more expensive.

Right alongside this, Radiant Energy Group just released their updated feasibility and cost report for restarting Germany's 14 remaining reactor units. It's quite the read and the link is in the header for those who want to deep-dive.

They sort the fleet into three priority groups by condition and restart complexity:

Group A (5 PWRs, 6.83 GW): Brokdorf, Emsland, Grohnde, Neckarwestheim 2, Isar 2. Most recently shut down, least decommissioning progress, shared design lineage enabling fleet efficiencies.
Total restart cost: €8.5 billion, online before 2032.

Group B (3 BWRs, 3.92 GW): Krümmel, Gundremmingen B and C. Similar cost profile to Group A but without the fleet-build efficiencies, smaller BWR workforce.
Total: €5.0 billion, online by 2033.

Group C (6 reactors, 7.96 GW): Biblis A and B, Philippsburg 2, Unterweser, Grafenrheinfeld, Neckarwestheim 1. These need extensive rebuilding, including new nuclear steam supply systems and in some cases new reactor pressure vessels.
Total: €25.8 billion, online 2033-2034.

The whole shebang: 14 reactors, 18.7 GW restored, ~147 TWh/year of firm dispatchable generation at €39 billion.

And every single reactor in the programme produces electricity below Germany's current wholesale price of ~€90/MWh. Groups A and B actually come in below the inflation-adjusted 2010s average of €51/MWh.

Meanwhile, German May futures traded at ~€87/MWh while French May futures sat at ~€22/MWh. Roughly 4x.

The 147 TWh/year from the full restart programme beats what either wind (~130 TWh) or solar (~90 TWh) added to the German grid over two decades of buildout. Delivered within ten years of a political decision, and unlike wind and solar, it's firm and available around the clock.

It also replaces Germany's ~90 TWh of remaining coal generation, making the Kohleausstieg achievable by the mid-2030s without relying on gas plants that haven't been built yet, which of course would run on LNG shipped in from outside the EU.

The report also kills the "too far gone" dismissal. German PWRs were designed from the outset for large-component replacement. Steam generators, pressurisers, pumps, turbines and I&C systems have all been routinely replaced at operating plants worldwide. Even the reactor pressure vessel was originally installed through equipment airlocks that still exist, so removal and replacement is physically possible.

Germany's deindustrialisation numbers keep getting worse. Output in energy-intensive industries has fallen 15.2% since February 2022, costing 53,300 jobs and a DIHK survey of nearly 3,600 companies found 59% of large industrial firms are considering cutting production or relocating abroad, up from 37% in 2022. The Bundesrechnungshof projects another €460 billion in grid expansion costs alone by 2045.

But sure, Germany can't fix this..because it just can't, apparently. If this is Germany in the 21st century, then we are all of us here in Europe in deep trouble.

Efter tre børn, hvoraf den yngste nu er ved at gå over til at bruge voksenstørrelser fremover, leder vi efter den nemmeste måde at komme af med en hel masse legetøj (f.eks. IKEA-køkken), sko, samt baby- og børnetøj. Ideelt set vil jeg gerne af med det hele i store portioner og undgå, at det bliver til et evigt langt loppemarked. Det er alt sammen i god kvalitet og passet godt på (Petit Bateau tøj, Bisgaard fodtøj osv.). Hvad er den bedste måde at gribe det an på ifølge jer eksperter derude? Facebook Marketplace? Reshopper?